Clinigen Group PLC
Records under this name other than the patents Clinigen Group PLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,906,515 | Cancer treatment with topoisomerase-II inhibitor, a bis-dioxypiperazine and radiation Term ended Term ended Mar 2, 2025 · From the USPTO record | Term ended | Term ended Mar 2, 2025 | From the USPTO record |
| US 7,053,072 | Methods for the Administration of Amifostine and Related Compounds Term ended Term ended Nov 5, 2022 · High confidence | Term ended | Term ended Nov 5, 2022 | High confidence |
| US 7,678,779 | Methods for the Administration of Amifostine and Related Compounds Term ended Term ended May 31, 2022 · High confidence | Term ended | Term ended May 31, 2022 | High confidence |
| US 7,368,440 | Methods for the Administration of Amifostine and Related Compounds Term ended Term ended May 8, 2022 · High confidence | Term ended | Term ended May 8, 2022 | High confidence |
| US 6,218,377 | Methods for the administration of amifostine and related compounds Term ended Term ended Jun 5, 2020 · From the USPTO record | Term ended | Term ended Jun 5, 2020 | From the USPTO record |
| US 6,727,253 | Treatment of accidental extravasation of anthracyclines Term ended Term ended Mar 13, 2020 · From the USPTO record | Term ended | Term ended Mar 13, 2020 | From the USPTO record |
| US 6,753,323 | Topical Administration of Amifostine and Related Compounds Term ended Term ended Sep 27, 2019 · Medium confidence | Term ended | Term ended Sep 27, 2019 | Medium confidence |
| US 7,151,094 | Topical Administration of Amifostine and Related Compounds Term ended Term ended Sep 15, 2019 · Medium confidence | Term ended | Term ended Sep 15, 2019 | Medium confidence |
| US 6,239,119 | Topical administration of amifostine and related compounds Term ended Term ended Apr 26, 2019 · From the USPTO record | Term ended | Term ended Apr 26, 2019 | From the USPTO record |
| US 6,265,385 | Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy Term ended Term ended Mar 8, 2019 · From the USPTO record | Term ended | Term ended Mar 8, 2019 | From the USPTO record |